

Low Penetration of FFR (1A Class) in Real Practice; Why and How to Overcome?

Jung-Min Ahn, MD.

Division of Cardiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea

FFR (or iFR) Guideline

AHA/ACC Guideline 2021

Recommendations for the Use of Coronary Physiology to Guide Revascularization With PCI

Referenced studies that support the recommendations are summarized in [Online Data Supplement 5](#).

COR	LOE	Recommendations
1	A	1. In patients with angina or an anginal equivalent, undocumented ischemia, and angiographically intermediate stenoses, the use of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) is recommended to guide the decision to proceed with PCI. ¹⁻⁶
3: No benefit	B-R	2. In stable patients with angiographically intermediate stenoses and FFR >0.80 or iFR >0.89, PCI should not be performed. ⁷⁻¹⁰

ESC Guideline 2018

Recommendations	Class ^a	Level ^b
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. ^{15,17,18,39}	I	A
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. ^{29,31}	IIa	B
IVUS should be considered to assess the severity of unprotected left main lesions. ³⁵⁻³⁷	IIa	B

Fract

Bernard De
Pim A.L. Ton
Nils Witt
Kreton Mav
Jane B.J

BACKGROUND
The preferen
best availab
significant s
percutaneous
would be su

METHODS
In patients w
was assessed
was function
PCI plus the
therapy alone
more than 0
therapy. The
urgent revas

RESULTS
Recruitment
underwent r
between-gro
point event-
ratio with P
ference was
in the medic
P<0.001); in
gered by a r
(hazard ratio
3.0% had a

CONCLUSION
In patients w
FFR-guided
available me
patients wit
available me
number, NC

1208

Downloaded

128

Downloaded

250

Downloaded

MEASUREMENT OF I

NICO H.J. P
PEPIJN H. VAN DER

Abstract Background. Coronary-artery stenoses of r
cut to determine. Myocardia
is a new index of the funct
nos that is calculated
made during coronary art
index with the results of
used to detect myocardia
usefulness of the index.

Methods. In 45 consec
coronary stenosis and che
performed bicycle exercise
stress echocardiography v
tive coronary arteriograph
with measurements of FFR

Results. In all 21 patie
0.75, reversible myocardia

The authors' full names, acad
degrees, and affiliations are list
Appendix. Address reprint requ
De Bruyne at the Cardiovascul
Aalst, Orze-Lieve-Vrouw Clinic,
baan 164, B-9300 Aalst, Belgi
bernard.de.bruyne@olvz-aalst.

*A full list of the FAME 2 invest
provided in the Supplementar
dix, available at NEJM.org.

Drs. Xaplanteris and Fournier
Jüni and De Bruyne contribute
to this article.

This article was published on May
at NEJM.org.

N Engl J Med 2018;379:250-9.
DOI: 10.1056/NEJMoa1803533
Copyright © 2018 Massachusetts Medic

The authors' full names, acad
degrees, and affiliations are list
Appendix. Dr. Fearon can be
at wfearon@stanford.edu or a
University School of Medicine,
teur Dr., H2103, Stanford, CA 9

The authors' affiliations
Appendix. Address reprint
De Bruyne at the Cardia
Aalst, Moorselbaan 164,
Belgium, or at bern
olvz-aalst.be.

*A complete list of in
committee members
Flow Reserve versus
Multivessel Evaluation
is provided in the Suppl
dix, available at NEJM.o

This article was published
2014, and updated on Sep
at NEJM.org.

N Engl J Med 2014;371:120
DOI: 10.1056/NEJMoa1408
Copyright © 2014 Massachus

CME
at NEJM.org

IN patients with chest p
severity as assessed by
uation and treatment are
agnostic tests are perform
the cause of the chest p
number of patients, coro
formed without definite ex
nosis is causing the symp

On the basis of pressu
stenoses during maximal
dial fractional flow reserv
as an invasively determin
verity of coronary steno
maximal blood flow to the
of a stenosis in the suppl
distribution. This index r
normal maximal myocardi
despite the coronary steno

FFR can be derived eas
distal coronary-artery pre
during maximal vasodila
pendent of changes in s
heart rate and is unaffec
crease the base-line myoc
takes into account the c
blood supply to maximal
normal value of the inde
tient or the specific vessel
lected patients undergoi

From the Department of Cardiol
Netherlands (N.H.J.P., K.P., P.H.V., H
Center, Aalst, Belgium (B.B., J.B.). A
Department of Cardiology, Catharin
hoven, the Netherlands.

Supported in part by a grant (94-
Hart, Eindhoven, the Netherlands.

JO

ESTABLISH

Fract
for C

Pim A.
Uwe Siebert, M.D.,
Ganesh Manohara
Philip A. Mad

BACKGROUND
In patients with multiv
ous coronary interven
guiding the placement
fractional flow reserve
normal maximal flow

METHODS
In 20 medical centers,
patients with multives
of drug-eluting stents g
in addition to angiogra
fied on the basis of the
phy-guided PCI underv
to FFR-guided PCI und
or less. The primary en
and repeat revasculariz

RESULTS
The mean (±SD) numb
raphy group and 2.8±1
patient was 2.7±1.2 and
(91 patients) in the ar
(P=0.02). Seventy-eigh
from angina at 1 year,

CONCLUSIONS
Routine measurement o
are undergoing PCI wit
posite end point of dea
tion at 1 year. (Clinica

The authors' full names, academi
degrees, and affiliations are listed in
Appendix. Address reprint requests to Dr.
Davies at Hammersmith Hospital, Imp
College London, London W12 0HS,
United Kingdom, or at justindavies@
heart123.com.

This article was published on March 18,
2017, at NEJM.org.

N Engl J Med 2017;376:1824-34.
DOI: 10.1056/NEJMoa1700445
Copyright © 2017 Massachusetts Medical Society.

1824

Downloaded

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812

MAY 11, 2017

VOL. 376 NO. 19

Instantaneous Wave-free Ratio versus Fractional Flow Reserve
to Guide PCI

M. Götberg, E.H. Christiansen, I.J. Gudmundsdottir, L. Sandhall, M. Danielewicz, L. Jakobsen, S.-E. Olsson,
P. Öhagen, H. Olsson, E. Omerovic, F. Calais, P. Lindroos, M. Maeng, T. Tödt, D. Venetsanos, S.K. James,
A. Käregren, M. Nilsson, J. Carlsson, D. Hauer, J. Jensen, A.-C. Karlsson, G. Panayi, D. Erlinge, and O. Fröbert,
for the iFR-SWEDEHEART Investigators*

ABSTRACT

BACKGROUND

The instantaneous wave-free ratio (iFR) is an index used to assess the severity of coronary-artery stenosis. The index has been tested against fractional flow reserve (FFR) in small trials, and the two measures have been found to have similar diagnostic accuracy. However, studies of clinical outcomes associated with the use of iFR are lacking. We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subsequent major adverse cardiac events.

METHODS

We conducted a multicenter, randomized, controlled, open-label clinical trial using the Swedish Coronary Angiography and Angioplasty Registry for enrollment. A total of 2037 participants with stable angina or an acute coronary syndrome who had an indication for physiologically guided assessment of coronary-artery stenosis were randomly assigned to undergo revascularization guided by either iFR or FFR. The primary end point was the rate of a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization within 12 months after the procedure.

RESULTS

A primary end-point event occurred in 68 of 1012 patients (6.7%) in the iFR group and in 61 of 1007 (6.1%) in the FFR group (difference in event rates, 0.7 percentage points; 95% confidence interval [CI], -1.5 to 2.8; P=0.007 for noninferiority; hazard ratio, 1.12; 95% CI, 0.79 to 1.58; P=0.53); the upper limit of the 95% confidence interval for the difference in event rates fell within the prespecified noninferiority margin of 3.2 percentage points. The results were similar among major subgroups. The rates of myocardial infarction, target-lesion revascularization, restenosis, and stent thrombosis did not differ significantly between the two groups. A significantly higher proportion of patients in the FFR group than in the iFR group reported chest discomfort during the procedure.

CONCLUSIONS

Among patients with stable angina or an acute coronary syndrome, an iFR-guided revascularization strategy was noninferior to an FFR-guided revascularization strategy with respect to the rate of major adverse cardiac events at 12 months. (Funded by Philips Volcano; iFR SWEDEHEART ClinicalTrials.gov number, NCT02166736.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Götberg at the Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, 222 41 Lund, Sweden, or at matthias.gotberg@med.lu.se.

*A complete list of participating centers and investigators in the Instantaneous Wave-free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome (iFR-SWEDEHEART) trial is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on March 18, 2017, at NEJM.org.

N Engl J Med 2017;376:1813-23.
DOI: 10.1056/NEJMoa1616540
Copyright © 2017 Massachusetts Medical Society.

NEW ENGL J MED 376:19 NEJM.ORG MAY 11, 2017

1813

The New England Journal of Medicine
Downloaded from nejm.org on May 5, 2023. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.





FFR (or iFR)

- Minimum Scientific and Ethical Safeguards to Avoid Unnecessary PCI
- No Benefit of PCI: FFR > 0.80 or iFR > 0.89


Clinical Benefit of FFR (1)

ASAN PCI Registry




Clinical Benefit of FFR (2)


Death



Myocardial Infarction




Repeat Revascularization



- The benefit of FFR guided PCI is primarily due to
 - 1) The reduced number of stents used per patients
 - 2) The subsequent decreased risk of peri-procedural MI and repeat revascularization


Clinical Benefit of FFR (3)

Meta-analysis from FAME2, DANAMI, COMPARE-Acute



No. at risk	0	1	2	3	4	5
Medical therapy	1344	1222	688	559	381	301
FFR-guided PCI	1056	980	696	566	406	328

Reduction of Spontaneous Myocardial Infarction



Eur Heart J . 2019 Jan 7;40(2):180-186.

Why the Penetration of FFR is Low ?

Revascularization in Stable Angina

PCI Failure or Trial Failure ?


COURAGE

FAME2

ISCHEMIA Trial

COURAGE Trial


Death from Any Cause and MI



No. at Risk

Medical therapy	1138	1017	959	834	638	408	192	30
PCI	1149	1013	952	833	637	417	200	35

Revasc. During FU
in Medication Group



Spontaneous MI


Medication: 119

PCI: 108

Boden et al. New Engl J Med 2007;356:1503-16.


FAME 2 Trial

Death from Any Cause



No. at Risk		0	1	2	3	4	5
Medical therapy	441	432	426	416	347	343	
PCI	447	439	431	422	360	352	

Revasc. During FU
in Medication Group



Spontaneous MI


Medication: 54

PCI: 29

P. Xaplanteris et al. N Engl J Med 2018;379:250-9


ISCHEMIA Trial

Death from Any Cause



No. at Risk	0	1	2	3	4	5
Conservative strategy	2591	2548	2065	1445	844	349
Invasive strategy	2588	2518	2061	1431	827	317

Revasc. During FU
in Medication Group




Spontaneous MI

Medication: 196

PCI: 130

Boden et al. New Engl J Med 2007;356:1503-16.

Revascularization in Medication Group





Reduction of Spontaneous MI

Trial	Hazard Ratio
COURAGE Trial	≈ 0.89 (?)
FAME2 Trial	0.62 (0.39-0.99)
Meta*	0.59 (0.42-0.83)
ISCHEMIA Trial	0.67 (0.53-0.83)
COMPLETE Trial	0.68 (0.53-0.86)

Non culprit lesion revascularization in STEMI with MV

* Meta-analysis from FAME2, DANAMI, COMPARE-Acute
Eur Heart J . 2019 Jan 7;40(2):180-186.

Natural History of Stable Angina Patients with Moderate to Severe Ischemia Under OMT



Severe IHD that Can Affect Worse Prognosis Were **Excluded** in the Trials

Major Exclusion Criteria

COURAGE

- Persistent CCS IV
- High-risk stress test
- LM disease
- EF <30%
- Refractory HF

FAME II

- CABG indicated
- LM disease
- LVEF <30%


ORBITA

- Multi-vessel ds
- LM disease
- LV dysfunction

ISCHEMIA


- NYHA III-IV HF
- Refractory Angina
- LM disease
- EF <35%

Left Main Coronary Stenosis: Meta-analysis



Circulation. 2013;127:2177-2185


Ischemic cardiomyopathy (EF < 35%): STICH Trial





N Engl J Med 2016;374:1511-20

Treatment of SIHD

OMT plus Risk Factor Modification (Default Treatment)



Impact of COURAGE and ORBITA Trials




J Am Heart Assoc. 2022;11:e025426. DOI: 10.1161/JAHA.122.025426


Doctors (Humans) are like that.
They don't change easily.

Appropriateness of PCI


From NCDR CathPCI Registry(N=500,154)



Since the publication of the Appropriate Use Criteria for Coronary Revascularization in 2009, there have been significant reductions in the volume of nonacute PCI




Hospital acute PCI volume, median No. (IQR)	2009	2010	2011	2012	2013	2014
	177 (101-289)	402 (246-629)	389 (255-614)	407 (264-627)	401 (262-620)	403 (265-620)



Hospital nonacute PCI volume, median No. (IQR)	2009	2010	2011	2012	2013	2014
	39 (20-72)	84 (46-151)	72 (39-127)	60 (34-107)	55 (29-100)	53 (27-98)

Current Status of FFR Penetration (1)



Use of FFR wire
(Abbott)

2019Y: 1238

2020Y: 1096

2021Y: 1214

2022Y: 1196

Current Status of FFR Penetration (2)



TABLE 1 Public Reporting of Coronary Physiology Uptake

Country (Ref. #)	Year	PW	PCI	PW/PCI	Temporal Change	Hospital-Level Reporting?
Sweden (9)	2017	NR	NR	26%	3.1-fold in 10 yrs	Yes
United Kingdom (10)	2016	18,811	100,483	19%	3.5-fold in 8 yrs	Yes
Italy (11)	2016	11,000	218,751	5%	1.4-fold in 4 yrs	Yes
Europe EAPCI (12)	2015	NR	889,957	16%	2-fold in 5 yrs	Per country
United States (13)	2014	3,465*	NR	31%	3.8-fold in 5 yrs	No
Australia (14)	2015	NR	3,869	19%	100-fold in 9 yrs	Per state

Gradually, People Are Changing.

Current Status of FFR Penetration (3)



SCAAR Registry (>30%)



J Am Coll Cardiol 2020;75:2785–99



Current Status of FFR Penetration (4)

Veterans Affairs Registry (>70%)




Current Status of FFR Penetration (5)

The **Korea** National Health Insurance Service Database (5% !!)



Nationwide Trends of Gatekeeper to Invasive Coronary Angiography in Suspected Coronary Artery Disease



EDITORIAL COMMENT

Coronary Psychology

Do You Believe?*



Nils P. Johnson, MD, MS,^a Bon-Kwon Koo, MD, PhD^b

“Why don’t physicians follow clinical practice guidelines?” That question—the title of a broad data review and synthesis (1)—remains as valid today as it was almost 20 years ago when posed. The Cabana et al. (1) framework connected 3 major steps along a path: knowledge (understanding what do to), attitude (believing that it should be done), and behavior (actually doing it). At each step, potential barriers can thwart the desired action. Given the enormous evidence base supporting coronary physiology, its perceived underuse in clinical practice has led to a multitude of explanatory theories, including hyperemic drugs, wire properties, and reimbursement. In this issue of *JACC: Cardiovascular Interventions*, the ERIS study from Italy (2) provides an important opportunity to examine new and old data for each of these hypothetical barriers.

SEE PAGE 1482

claimed it was due to a knowledge barrier (“I do not understand enough about FFR”). Additionally, <5% of responses identified attitude barriers, for example “I do not trust FFR.” Instead, the dominant responses focused on reimbursement and the time necessary to perform the procedure. A logical conclusion from this survey was that we should focus on environmental barriers to improve the penetrance of coronary physiology.

However, surveys may not accurately reflect behavior, as recently demonstrated by polling mis-cues in the United States election and the Brexit vote. A subsequent European study called the ISIS study (4) asked interventional cardiologists to make clinical decisions when provided with an angiogram showing an intermediate lesion in a stable patient. Importantly, the decisions were to be made “assuming ideal world conditions, without considering any financial restrictions or local regulations, but only after the


Coronary *psychology*

What *really works*?


- more studies/trials
- training or conferences
- guideline or consensus
- insurance reimbursement
- media coverage
- legal action
- public registry
- simplify (avoid hyperemia)
- better wires

How to Overcome Low Penetration of FFR?

Current Status of FFR Penetration (6)




PCI Trend in US and JAPAN




Inohara, T. et al. J Am Coll Cardiol. 2020;76(11):1328-40.

The Policy Change for Ischemia Assessment in Japan

A Proportion of planned PCI with ischemia assessment



B Number of planned PCI analyzed



The Japanese Ministry of Health, Labour, and Welfare introduced a new reimbursement policy: to reduce unnecessary PCIs, ischemia assessment (**unless stenosis was very tight**) was required for planned PCI beginning in April 2018

Although the database did not include test results of ischemia assessment or details of PCI-associated complications, the total number of planned PCIs decreased without an increase in all-cause mortality after implementation of the new reimbursement policy.

Our results have a potential clinical benefit because the policy change led to a reduction in the number of unnecessary PCIs in patients with coronary artery disease